FDA approves OCREVUS™ (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis

Roche announced as of March 28, 2017 that the US Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. The MS Center of Northeastern NY has participated in the Ocrelizumab clinical drug trials since 2011. We are the only center in the Capital region and beyond that has the expertise with ocrelizumab. Click here to see our latest advertisement on the Times Union.